Bollard Group LLC Takes Position in Disc Medicine, Inc. $IRON

Bollard Group LLC bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,635 shares of the company’s stock, valued at approximately $1,622,000. Bollard Group LLC owned about 0.09% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its stake in Disc Medicine by 13,428.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company’s stock worth $47,000 after buying an additional 940 shares during the period. CWM LLC boosted its stake in shares of Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after purchasing an additional 711 shares during the period. Avanza Fonder AB bought a new position in Disc Medicine during the 2nd quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after purchasing an additional 181 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of IRON stock opened at $93.26 on Friday. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $97.11. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $83.46 and a two-hundred day simple moving average of $65.86. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -17.43 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IRON shares. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Wedbush boosted their price objective on Disc Medicine from $90.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Stifel Nicolaus initiated coverage on Disc Medicine in a research note on Monday, November 3rd. They issued a “buy” rating and a $125.00 target price on the stock. National Bankshares set a $153.00 target price on shares of Disc Medicine in a research note on Friday, October 17th. Finally, Cantor Fitzgerald upped their price target on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $119.10.

Insider Activity

In other news, COO Jonathan Yen-Wen Yu sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $84.70, for a total value of $2,541,000.00. Following the completion of the sale, the chief operating officer owned 40,555 shares of the company’s stock, valued at approximately $3,435,008.50. This represents a 42.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Bitterman sold 70,000 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the completion of the transaction, the director directly owned 385,549 shares of the company’s stock, valued at $34,279,161.59. This trade represents a 15.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 213,585 shares of company stock valued at $16,898,513. Company insiders own 3.64% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.